Bayer AG

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bayer AG engages in the business of life science fields of healthcare and nutrition. It operates through the following segments: Crop Science, Pharmaceuticals, and Consumer Health. The Crop Science segment includes developing, producing, and marketing products in seeds and plant traits, crop protection, digital solutions, and customer services to promote sustainable agriculture. The Pharmaceuticals segment is involved in prescription products especially for cardiology and women’s health; specialty therapeutics in the areas of oncology, hematology, ophthalmology, and cell and gene therapy; diagnostic imaging equipment; and necessary contrast agents. The Consumer Health segment focuses on non-prescription products in the dermatology, nutritional supplements, digestive health, allergy, cough and cold, and pain and cardiovascular risk prevention categories. The company was founded by Friedrich Bayer and Johann Friedrich Westkott on August 1, 1863 and is headquartered in Leverkusen, Germany.

Bayer bowed to investor pressure on Wednesday and named Bill Anderson, most recently head of Roche's pharmaceuticals business, to take over from Werner Baumann as its CEO in June.

Factbox: Bayer's new CEO: long-time Roche, Genentech executive, Bill Anderson

Bayer stock surged to an eight-month high Wednesday after the company named former Roche exec Bill Anderson as its new chief executive. The post Bayer Snags Ex-Roche Exec Bill Anderson As New CEO; Shares Rocket appeared first on Investor's Business Daily.

Bayer Snags Ex-Roche Exec Bill Anderson As New CEO; Shares Rocket

New Chief Executive Bill Anderson will confront the company's legal troubles and its $43 billion in debt.

Bayer to Replace CEO Werner Baumann With Former Roche Executive

LEVERKUSEN, Germany--(BUSINESS WIRE)--The Supervisory Board of Bayer AG has appointed Bill Anderson to become CEO of Bayer, effective June 1, 2023. He will join Bayer as a member of the Board of Management on April 1, 2023. Bill Anderson was elected unanimously after a thorough selection process which began mid last year. Werner Baumann (60), current CEO of Bayer, will work closely with him on a smooth transition before retiring from Bayer after 35 years of service at the end of May 2023.

Bill Anderson to Become CEO of Bayer AG

Germany's Bayer on Wednesday named Bill Anderson, most recently head of Roche's pharmaceuticals division, to succeed Werner Baumann as its chief executive on June 1.

Germany's Bayer picks Bill Anderson to succeed Baumann as CEO

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced the first patients have been enrolled in its OCEANIC clinical trial program, which will explore the use of asundexian in AF and TIA.

Bayer Announces First Patients Enrolled in Global Phase III Studies for Investigational Oral FXIa Inhibitor Asundexian

ST. LOUIS--(BUSINESS WIRE)--In time for the 2023 cotton planting season, Bollgard® 3 ThryvOn™ cotton with XtendFlex® Technology is now commercially available. ThryvOn Technology provides built-in protection and may reduce the number of insecticide applications needed for control of key tarnished plant bug and thrips species.*

Bayer Announces Full Commercialization of ThryvOn™ Technology in the U.S., a Unique Cotton Biotech Trait Set to Launch for 2023 Growing Season

Bayer investor Jeff Ubben has contacted fellow shareholders in the German group, investors and sources familiar with the matter told Reuters, in an apparent attempt to rally support for big changes at the drugs-to-pesticides company.

Activist investor rallies Bayer shareholders as pressure on CEO mounts -sources

Bayer investor Deka has called for CEO Werner Baumann to be replaced ahead of his scheduled departure, adding to mounting pressure on the German drugmaker.

Bayer investor calls for swift replacement of CEO -newspaper

ST. LOUIS--( BUSINESS WIRE )--Bayer today announced that Ben Kampelman, formerly Director, Strategic Communications for Crop Science North America, has been appointed to the role of Vice President of Communications, Crop Science North America.

Bayer Appoints Ben Kampelman as Vice President of Communications for Crop Science North America

The Bayer investor Union Investment criticized Bayer's chair for a lack of engagement, such as exploring a spin-off of the company's consumer health division, according to an interview in WirtschaftsWoche.

Bayer investor criticizes Bayer chair for lack of initiative - WirtschaftsWoche

Jeff Ubben's Inclusive Capital took a stake in Bayer. The pharmaceutical giant has a big footprint in the crop science space.

Inclusive Capital takes a stake in Bayer — 3 ways it may build value with a sustainable focus

Investor hopes are once again rising that some kind of breakup could start to close the valuation discount at which the embattled German company trades.

Bayer Could Go the Way of General Electric and Daimler

Bayer stock is poised to see strong buyer interest, as the company raised its peak sales forecast for new pharmaceutical drugs. Investor sentiment is also positively impacted by news that activist investors Bluebell Capital Partners and Inclusive Capital Partners were advocating for a partial company break up and a replacement of CEO Werner Baumann with a 'Bayer outsider'.

Bayer: A Strong Buy Now

PITTSBURGH--( BUSINESS WIRE )--Bayer today announced the acquisition of the global strategic imaging AI platform and solutions provider Blackford Analysis Ltd. The acquisition is part of Bayer's strategy to drive innovation in radiology, including the development and adoption of AI within the clinical workflow, with the goal to ultimately improve patient care and advance Bayer's position in digital medical imaging.

Bayer Acquires Blackford Analysis Ltd. Bolstering the Company's Position in Digital Medical Imaging

Eli Lilly

BAYRY vs. LLY: Which Stock Is the Better Value Option?

BAYRY or LLY: Which Is the Better Value Stock Right Now?

AstraZeneca

These big pharmaceuticals are poised for back-to-back big years.

3 Growth Stocks Poised for Huge Gains in 2023

Bayer shares gained 1.7% in early Wednesday trade following a report activist investor Bluebell Capital Partners has built an equity stake and is pushing for a break-up of the German pharmaceutical and agriculture company.

Bayer gains on report activist Bluebell pushing for break-up

Sanofi

CAMBRIDGE, Mass. & LEVERKUSEN, Germany--( BUSINESS WIRE )--NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. The financing will be used to advance NextPoint's two lead precision immuno-oncology programs into the clinic, both targeting the newly discovered HHLA2 pathway to activate anti-tumor immune responses.

NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures to Advance Novel Immuno-Oncology Programs

Ambev

Anheuser-Busch InBev

Experian PLC

James Hardie Industries

MercadoLibre

Novozymes A/S

Roche Holding AG

Royal Bank of Canada

Tencent Holdings Limited

Toronto-Dominion Bank

Taiwan Semiconductor Manufacturing

Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating). We are only interested in those targets that are attractively valued in historical comparison.

International Wide-Moat Stocks On Sale - The January 2023 Heat Map

Apple

AbbVie

AGNC Investment

AGNC Investment Corp - FXDFR PRF PERPETUAL USD 25 - Ser D 1/1000th int

AGNC Investment Corp. Deposit Shs Repr 1/1000th Cum Conv Red Pfd Registered Shs Series C

Allianz SE

Antero Midstream Partners

Apple Hospitality REIT

Ares Capital

Apollo Commercial Real Estate Finance

Broadcom

Boeing

Alibaba

Bank of America

BASF SE

Brookfield Renewable Partners

B&G Foods

Brookfield Infrastructure Partners L.P.

Bank of Montreal

Inflation and (expected) actions by the Federal Reserve continue to dominate market movements. Markets remain very volatile following record inflation readings paired with an aggressive Fed and negative consumer sentiment.

My Dividend Stock Portfolio: New December Record - 96 Holdings With 24 Buys, 6 Sales

Abbott Labs

Alnylam Pharmaceuticals

Amgen

argenx

Baxter

BeiGene

Biogen

Bristol-Myers

United States Brent Oil Fund LP

BioNTech SE

CSL Ltd

Invesco DB Oil Fund

Daiichi Sankyo Co Ltd

Gilead Sciences

Genmab - ADR

Direxion Daily S&P Oil & Gas Exp. & Prod. Bull 2X Shares

iShares U.S. Oil & Gas Exploration & Production ETF

Incyte

Johnson & Johnson

Merck

Moderna

Novo Nordisk

Novartis

VanEck Vectors Oil Services ETF

iPath Pure Beta Crude Oil ETN

Pfizer

Invesco Dynamic Oil & Gas Services ETF

Reckitt Benckiser Group PLC

Regeneron Pharmaceuticals

Royalty Pharma

Seagen

Takeda Pharmaceutical

ProShares Ultra Bloomberg Crude Oil

United States Oil Fund LP

Vertex Pharmaceuticals

SPDR S&P Oil & Gas Exploration & Production ETF

Medical and energy companies, including oil stocks, lead the list of the 100 best stocks in 2022. The post 100 Best Stocks Of 2022: Oil Stocks And Medicals Shine appeared first on Investor's Business Daily.

100 Best Stocks Of 2022: Oil Stocks And Medicals Shine

With economic worries unsettling investors, it is not surprising that leading advisors, and contributors to MoneyShow.com, are looking to the pharmaceutical sector – Here's a look at seven global favorites, focused on such areas as obesity and diabetes to new applications for mRNA-based vaccines.

7 Healthy Buys Among Global Drug Makers

BERKELEY, Calif.--( BUSINESS WIRE )--Bayer will invest more than $1.5 million in Berkeley working with 13 non-profits to drive resiliency in its West Berkeley neighborhood and to advance Science, Technology, Engineering, Arts and Math (STEAM) education over the next three to five years. Sponsorship of these programs is part of Bayer's recently Amended and Restated Development Agreement (ARDA) with the City of Berkeley which outlines more than $33 million in community investments to be made over the next 30 years as the company transforms its biotech operations there.

Bayer to make more than $1.5 Million in Investments in STEAM Education and West Berkeley Resiliency

The Roundup acquisition has cost Bayer AG billions in lawsuits; however, this seems to be coming to an end as the company has been winning most cases recently. Bayer boasts a strong and improving balance sheet with a P/B ratio of just 1.26 and IP with a strong moat. Furthermore, earnings and free cash flow are rising.

Bayer AG: Turnaround Value Stock

News for Bayer AG Stock (BAYRY)